2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 98

The Mitochondrial DNA (mtDNA) Haplogroups Influence the Risk of Incidence Knee OA. Replication Study Including Data from Check and OAI Cohorts

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 111

The Mitochondrial DNA (mtDNA) Haplogroups Influence the Risk of Radiographic OA Progression. a Meta-Analysis

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 112

The Molecular Genetic Analysis of the Autoinflammatory Syndromes in Russian Patients with Manifestation of Systemic Juvenile Idiopathic Arthritis

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 618

The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 2

The Neutrophil Protein S100A12 Has Stronger Associations with a Comprehensive Ultrasound Score of Synovitis Than Vascular Endothelial Growth Factor in a Longitudinal Study of Rheumatoid Arthritis Patients

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 6

The Novel Role of Corticotropin-Releasing Hormone and Urocortin1 on Sjogren’s Syndrome

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 652

The Performance of Different Classification Criteria Sets for Spondyloarthritis in the Worldwide ASAS-Comospa Study

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 651

The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 256

The Predominant Attack Type and Associated Clinical-Laboratory Conditions in Patients with Familial Mediterranean Fever

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 740

The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 237

The Prevalence of Chondrocalcinosis of the Symphysis Pubis on CT Scan and Correlation with Calcium Pyrophosphate Dihydrate Crystal Deposition Disease

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 44

The Prevalence of Depression and Anxiety in a Cross-Section of Rheumatological Conditions

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 196

The Pyrin Domain-Only Protein POP1 Inhibits NLRP3-Dependent Inflammatory Disease

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 611

The Rapid Kinetics of Optimal Treatment with Subcutaneous Methotrexate in Early Inflammatory Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 757

The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].